RxDoctor Payments Data

Saunder Bernes

Neurology with Special Qualifications in Child Neurology · Phoenix, AZNPI 1700848868

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Sarepta Therapeutics, Inc. at 48.0% of the total. Reporting peaked in 2023 at $10,352 and has fallen 58.6% since, to $4,288 in 2025. Among neurology with special qualifications in child neurology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$27,441in general payments, 2019–2025

Across 71 payments — averaging $386.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sarepta Therapeutics, Inc.$13K
  • Genentech USA, Inc.$6K
  • UCB, Inc.$3K
  • Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$3K
  • CSL Behring$600
  • Biogen$256
  • plus $577 from 8 others
$672,372in research payments, 2019–2025

Across 232 payments — averaging $2898.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$226K
  • PTC Therapeutics, Inc.$140K
  • Janssen Research & Development, LLC$126K
  • Novartis$70K
  • Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$47K
  • Genentech, Inc.$43K
  • plus $20K from 2 others

What the payments were for

  • Consulting fees$15,89058%
  • Speaking & faculty fees$8,79232%
  • Travel & lodging$1,0924%
  • Food & beverage$1,3285%
  • Education$3391%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,441 in reported general payments places this provider in the 90th percentile of 49 neurology with special qualifications in child neurology providers in Arizona.

See all neurology with special qualifications in child neurology providers in Arizona

Most prescribed under Part D

DrugClaimsCost to plans & patients
EvrysdiRisdiplam14$369,068
CarbatrolCarbamazepine12$2,600
Levetiracetam53$1,559
Lamotrigine13$223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Evrysdi$6,080$369,06814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 49 neurology with special qualifications in child neurology providers in Arizona.

Other neurology with special qualifications in child neurology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →